Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Smiths Detection today announces the award of a $2.2m, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop a test for multiple types of influenza.
Critical illness among Canadian patients with 2009 influenza A(H1N1) occurred rapidly after hospital admission, often in young adults, and was associated with severely low levels of oxygen in the blood, multi-system organ failure, a need for prolonged mechanical ventilation, and frequent use of rescue therapies, according to a study to appear in the November 4 issue of JAMA.
Vioguard LLC, www.vioguard.com, is introducing the world’s first self-sanitizing computer keyboard to kill MRSA and other healthcare-associated infections (HAIs) at the American Association of Oral and Maxillofacial Surgeons (AAOMS) 91st annual meeting, October 12-17 in Toronto. The event marks the first availability of the innovative keyboard for medical market uses and consumers in Canada.
Members of Qatar's research and medical community recently gathered at Weill Cornell Medical College in Qatar to learn more about research conducted by the college's pre-medical and medical students.
People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.
While Americans anxiously await the arrival of the H1N1 Flu Vaccine in their area, many are seeking new methods to try to keep their homes germ free and their families healthy during this flu season.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
The global diagnostics industry has witnessed strong growth over the past few years. According to Frost & Sullivan, the diagnostics and monitoring sectors are poised to present more growth opportunities. According to Nitin Naik, Vice President of Frost & Sullivan's Asia Pacific Medical Technologies Division, the diagnostics and monitoring sectors in Asia Pacific are projected to provide more growth opportunities on the basis of the technology spending being channelled in these areas (80 percent).
Efforts by the U.S. Department of Education to encourage school preparedness for learning continuity during prolonged absences or emergency dismissals due to H1N1 flu outbreaks included a recent tour of a closure simulation at VOISE Academy, a Chicago public school.
Swisher Hygiene, leading provider of commercial cleaning and sanitizing products and services, today announced the launch of H1N1 Basics, a free online course offering practical guidance to minimize the opportunity for transmission of H1N1 in the workplace.
The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.
Will a four-minute educational video about a team of Air Force researchers investigating the H1N1 influenza virus go "viral" with middle- and high-school students?
AvMed Health Plans announced that it will cover H1N1 flu administration fees for all of its fully insured members. Co-pays, co-insurance and deductibles will not apply for administration of the H1N1 vaccine even if they have a benefit plan that does not include immunizations.
About 100 low- and middle-income countries could receive donated shipments of the H1N1 (swine flu) vaccine as early as November, Marie-Paule Kieny, of the WHO, told journalists Monday, Agence France-Presse reports. "Dozens of millions of doses are being lined up following offers from pharmaceutical companies," including Sanofi-Aventis, GlaxoSmithKline and MedImmune, as well as a coalition of developed nations "that have pledged to release 10 percent of their vaccine purchases for poor nations," the news service writes (10/12).
Critical illness from 2009 influenza A(H1N1) in Mexico occurred among young patients, was associated with severe acute respiratory distress syndrome and shock, and had a fatality rate of about 40 percent, according to a study to appear in the November 4 issue of JAMA.
A federal health official downplays risks from swine flu vaccine while the demand for the vaccine causes shortages.
With the onset of the H1N1 virus, commonly known as the Swine Flu, more and more small businesses need to be prepared. That’s why Office Depot, a leading global provider of office products and services, is teaming up with Acme United to create the “Fight the Flu Kit.”
Allviant Corporation today announced the launch of its CarePass™ pilot program with Arizona State University to add another tool to the university’s health and wellness communications and services while empowering its employees and students with tools to manage their healthcare relationships.
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.
The Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital will host a public forum and scientific workshop Oct. 14 to 16 to discuss emerging issues of importance for the National Institutes of Health (NIH) for women's health research in the coming decade.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.